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INTRODUCTION
At presentation, the majority of bladder urothelial carci-
noma (BUC) is a superficial low- grade tumor which can often
be treated with transurethral resection (TUR) and, in some
cases, additional intravesical chemo- or immuno-therapy.
However, the tumor recurrence rate may be as high as 70%
to 80%, and 10% to 15% of recurrent BUC may progress
to a higher grade and/or stage, requiring radical cystectomy
in most cases (1). Consequently, long-term close surveillance
of patients with BUC is essential to manage tumor recurrences
and prevent invasive disease. 
Cystoscopy and cytology have been the standard diagnostic
tools for detection and monitoring of BUC. However, cysto-
scopy is an invasive technique and can miss the flat lesions
such as pTis. Cytology has remained the only alternative non-
invasive method for detecting primary BUC or recurrent dis-
ease. However, it lacks sensitivity for low-stage and low-grade
tumors (2, 3). Therefore, more sensitive and noninvasive me-
thods are under evaluation for the diagnosis and follow-up
of patients with BUC. Although many morphology-based,
biochemical and molecular methods, including the BTA test,
BTA stat, NMP 22 and immunocyt have been shown to be
more sensitive than cytology, for the detection of BUC, they
lack a comparable level of specificity (4-6).
Genetic abnormalities occur during the initial stages of
tumor development and are the primary determinants of neo-
plastic transformation. Fluorescence in situ hybridization
(FISH) is a cytogenetic-based technology that is used for the
analysis of multiple chromosomes in several cells. FISH uti-
lizes fluorescently labeled DNA probes that hybridize to the
centromeres of the chromosomes or unique loci to detect cells
with numerical or structural abnormalities indicative of malig-
nancy. Sokolova et al. (7) reported the development of a FISH
assay with high sensitivity and specificity for the detection
of UC, using four labeled probes, three centromeric probes
for chromosomes 3, 7, and 17 and a one locus-specific probe
for chromosome 9. The purpose of the present study was to
evaluate FISH for the detection of BUC in routine clinical
practice, and compare it to the standard cytology results.
MATERIALS AND METHODS
Patients and samples
Voided urine specimens from 493 patients were obtained
for FISH analysis and cytology examination between April
2006 and July 2007. Among these patients, those who did
not undergo cystoscopy (n=152), had a suspected lesion of
1139
Kyung Won Kwak
1, Sun Hee Kim
2, 
and Hyun Moo Lee
3
Department of Urology
1, KEPCO (Korea Electric Power
Corporation) Medical Foundation, Hanil General 
Hospital, Seoul; Departments of Laboratory Medicine
2
and Urology
3, Samsung Medical Center, Sungkyunkwan
University School of Medicine, Seoul, Korea
Address for correspondence
Hyun Moo Lee, M.D.
Department of Urology, Samsung Medical Center,
Sungkyunkwan University School of Medicine, 50
Irwon-dong, Gangnam-gu, Seoul 135-710, Korea
Tel : +82.2-3410-6543, Fax : +82.2-3410-3027
E-mail : besthml@medimail.co.kr
J Korean Med Sci 2009; 24: 1139-44
ISSN 1011-8934
DOI: 10.3346/jkms.2009.24.6.1139
Copyright � The Korean Academy
of Medical Sciences
The Utility of Fluorescence In Situ Hybridization for Detection of
Bladder Urothelial Carcinoma in Routine Clinical Practice
To evaluate the ability of fluorescence in situ hybridization (FISH) in detecting blad-
der urothelial carcinoma (BUC), FISH and cytology were compared for the evalua-
tion of 308 consecutive urine samples from patients suspected of having BUC. All
patients underwent cystoscopy for identification of bladder lesions. The FISH results
were compared with the cytology assessment. In all, 122 patients had confirmed
BUC. Among them, 68 (55.7%) were FISH-positive, while only 33 (27%) were posi-
tive on cytology. According to disease stage (superficial vs. invasive) and grade (low
vs. high), the sensitivities of FISH were also significantly higher than those of cytol-
ogy in all categories. Moreover, in 36 patients who had no visible tumor with flat,
erythematous mucosa (suspicious lesion), FISH was more sensitive than cytology
for the detection of BUC (83.3% vs. 33.3%, P=0.002). The FISH was negative in
168 (90.3%) of 186 patients with no histological evidence of BUC or negative cys-
toscopy findings. The sensitivity of FISH for detecting BUC was superior to that of
cytology, regardless of tumor stage and grade. FISH is a significant additional and
complementary method for detection of BUC in patients who have suspicious lesions
on cystoscopy. 
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the upper urinary tract on intravenous urography (IVU) or
abdominal ultrasonography (n=20), or were lost to follow-
up despite definite identification of bladder lesions on cys-
toscopy (n=13) were excluded from this study. Finally, void-
ed urine specimens from 308 patients (205 males and 103
females; mean age, 59.7±11.8 yr) were studied. All patients
provided their informed consent before participating in this
study. Of the 308 patients, the 61 that had a history of UC
(bladder: 54, upper tract: 7) and the 247 without a history
of UC were evaluated for symptoms suspicious of BUC (micro-
scopic/gross hematuria and obstructive/irritative voiding symp-
toms). All patients underwent cystoscopy for identification
of bladder lesions. One hundred and forty-two patients under-
went TUR or biopsies of abnormal bladder lesions. The FISH
results were compared with the cytological assessment based
on the histopathology and cystoscopy findings.
Cytology
Cytology samples were centrifuged (1,500 rpm for 5 min)
and stained using Papanicolaou’s technique. Cytopathologists
that were blinded to the patient’s clinical information and
the result of FISH evaluated the urine samples. The cytolo-
gy was classified as negative, atypical, suggestive of malig-
nancy, or positive. For the calculation of the sensitivity and
specificity, the cases that were interpreted as suggestive of
malignancy and positive were pooled together. 
FISH analysis
FISH was conducted using the instructions in the package
insert of the UroVysionTM Bladder Cancer Kit (Abott Molec-
ular Inc, Des Plaines, IL, U.S.A.). The volume of urine avail-
able for FISH was more than 33 mL. Cells from voided urine
were sedimented at 1,000 rpm for 10 min. Fresh Carnoy’s
fixative (3:1 [v:v] methanol:glacial acetic acid) was added to
the cell pellet; the pellet was mixed and resuspended. Fresh
fixative was added a second time; the cells were mixed and
placed at -20℃ for 30 min. To ensure appropriate cellular
density, 3, 10, and 30 μ L of the cell suspension were placed
into separate wells on slides. The individual wells were exam-
ined under phase contrast and the well demonstrating opti-
mal cell concentration was selected for investigation. Hybri-
dization was performed using UroVysionTM Bladder Cancer
Kit (Abott Molecular Inc). The UroVysion probe mixture
consists of Chromosome Enumeration Probe (CEP) 3 Spec-
trumRed, CEP 7 SpectrumGreen, CEP 17 SpectrumAqua
and Locus Specific Identifier (LSI) 9p21 SpectrumGold. The
probes are pre-mixed and pre-denatured in hybridization
buffer for ease of use. Unlabeled blocking DNA is also includ-
ed with the probes to suppress sequences contained within
the target loci that are common to other chromosomes. When
hybridized and visualized, these probes provide information
on chromosome copy number for chromosome ploidy enumer-
ation. Cells recovered from urine pellets were fixed on slides.
The DNA was denatured to its single stranded form and sub-
sequently allowed to hybridize with the UroVysion probes.
Following hybridization, the unbound probe was removed
by a series of washes, and the nuclei were counterstained with
DAPI (4, 6 diamidino-2-phenylindole) and viewed using a
fluorescent microscope. At least 25 morphologically abnor-
mal cells were scored. Two independent observers blinded
to the clinical information evaluated all samples. In case of
disagreement, both observers evaluated the sample again at
the same time. Slides were assessed by scanning for cytolog-
ically atypical nuclei (larger nuclear size, irregular nuclear
shape, and patchy DAPI staining) and then determining the
number of CEP3, CEP7, CEP17, and locus-specific probe
for chromosome 9 (LSI 9p21). The criteria for a FISH-posi-
tive result were those according to Zellweger et al. (8). A sam-
ple was considered positive for UC if at least one of the fol-
lowing criteria was met: 1) identification of four or more cells
with gains in two or more different chromosomes (3, 7 or 17),
2) observation of homozygous deletion of 9p21 in 12 or more
cells. 
Histopathology examination
Pathologists performed the histopathology evaluation on
the 142 patients who underwent TUR or biopsy. The stage of
BUC was determined based on the International Union Against
Cancer TNM classification and tumor grading defined as low
(grade 1 and grade 2) or high-grade (grade 3).
Statistical analysis
The sensitivity of FISH and cytology was determined for
the patients with pathology-proven UC, stratified for tumor
stage and grade. The specificity of FISH and cytology was
calculated for the patients with no histological confirmation
of UC or negative cystoscopy findings. The difference between
the two methods was determined by the McNemar test. A
P value <0.05 was considered statistically significant. SPSS
13.0 (SPSS Inc, Chicago, IL, U.S.A.) was used for statistical
calculations.
RESULTS
There were 142 patients with abnormal lesions on cys-
toscopy, and all of them underwent TUR or biopsy. One hun-
dred and sixty-six patients who did not undergo TUR or biop-
sy were negative on cystoscopy. Patients had lesions with a
variety of growth patterns, including papillary (n=79), nodu-
lar (n=14), sessile (n=13), and flat, erythematous mucosa with-
out visible tumor (n=36). In all, 122 patients had confirmed
BUC based on the pathology reports. The tumors were pTis
in six patients, pTa in 55, pT1 in 41, and pT2 in 20; 78 wereBladder Urothelial Carcinoma and FISH 1141
low-grade and 44 high-grade. 
Among the 122 patients with histologically confirmed UC,
30 were FISH-positive with the concurrent cytology results
suggestive of malignancy or positive (Fig. 1) and 38 FISH-
positive results were discordant (negative or atypical) with the
cytology results (Fig. 2). Sixty-eight patients among the 122
with UC were FISH-positive, resulting in an overall sensitivity
of 55.7%, while only 33 were positive by cytology (sensitiv-
ity: 27%). The difference in the sensitivity between FISH and
cytology was statistically significant (Table 1). In addition,
the sensitivities of FISH and cytology for the superficial tumors
(pTis, pTa, and pT1) were 52% and 25.5%, respectively (P<
0.001), while for the muscle-invasive tumors (pT2) they were
75% and 35%, respectively (P=0.021) (Fig. 3). Furthermore,
Fig. 1. A case with high-grade T1 (T1G3) urothelial carcinoma, cytology suggestive of malignancy, and positive FISH. Cytology, Pap stain
100×showing clusters of pleomorphic nuclei with large nucleoli, suggestive of malignancy (A). FISH shows four copies of chromosome
3 (red), three copies of chromosome 7 (green) and six copies of chromosome 17 (aqua) (B). Resected tumor (H&E, ×20) demonstrates
invasion of lamina propria by high grade tumor (C).
Fig. 2. A case with high grade Ta (TaG3) urothelial carcinoma, negative cytology, and positive FISH. Cytology, Pap stain 100×showing
normal urothelium, negative cytology (A). FISH shows four copies of chromosome 3 (red) and 7 (green), and three copies of chromo-
some 17 (aqua) (B). Resected tumor (H&E, ×20) shows papillary high-grade tumor confined to epithelium (C). 
A B C
A B C
*Results suggestive of malignancy considered as positive for sensitivity
calculation.
FISH, fluorescence in situ hybridization; UC, urothelial carcinoma.
FISH Cytology* P value
Overall patients (%)
Sensitivity 68/122 (55.7) 33/122 (27) <0.001
Specificity 168/186 (90.3) 182/186 (97.8) <0.001
Patients with history of prior UC (%)
Sensitivity 28/53 (52.8) 17/53 (32.1) 0.007
Specificity 5/8 (62.5) 7/8 (87.5) 0.500
Patients without history of prior UC (%) 
Sensitivity 40/69 (58.0) 16/69 (23.2) <0.001
Specificity 163/178 (91.6) 175/178 (98.3) <0.001
Patients with no visible tumor on cystoscopy (%)
Sensitivity 20/24 (83.3) 8/24 (33.3) 0.002
Specificity 10/12 (83.3) 12/12 (100) 1.000
Table 1. Sensitivity and specificity of FISH and cytology
Fig. 3. Sensitivity based on histologic stage.
FISH, fluorescence in situ hybridization; Superficial, Tis, Ta, and
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the sensitivities of FISH and cytology were 41% vs. 17.9%
for low-grade tumors, and 81.8% vs. 43.2% for high-grade
tumors, respectively (P<0.001, P<0.001, respectively) (Fig. 4). 
Thirty-six patients who had no visible tumor with flat, ery-
thematous mucosa (suspicious lesions) underwent TUR or
biopsies of the bladder lesion. Twenty-four of these patients
demonstrated BUC; low grade pTa in 6, high grade pTa in
1, low grade pT1 in 4, high grade pT1 in 4, pTis in 5, and
high grade pT2 in 4. Among them, FISH were positive in
20 (83.3%), however, the cytology was positive or sugges-
tive of malignancy in 8 cases (33.3%) (Table 1).
There were 61 patients with a history of UC in this popu-
lation. Fifty-three of them had documented recurrences and
28 (52.8%) of these patients were FISH-positive; with cytol-
ogy, 17 (32.1%) were suggestive of malignancy or positive
(P=0.007). In the analysis of the 247 patients evaluated for
suspicious symptoms without a history of UC, 69 had histo-
logically confirmed UC. The sensitivities of FISH and cytolo-
gy were 58% and 23.2%, respectively (P<0.001). Among
186 patients with no histological evidence for UC or had neg-
ative cystoscopy findings, FISH was negative in 168 (90.3%)
and cytology in 182 (97.8%). Although the specificity of
cytology was higher than that of FISH, the specificity of FISH
overall was 90.3%, and for the patients without a previous
UC it was 91.6%. 
DISCUSSION
The use of genetic analysis of urine cells has demonstrat-
ed specificity equivalent to that of cytology (9, 10). FISH is
used for the detection of cytogenetic abnormalities in malig-
nant cells. Several prior studies (10-12) have reported that
FISH was significantly more sensitive than cytology for the
detection of UC and that the specificity of FISH and cytolo-
gy were not significantly different. However, since the con-
firmation of higher sensitivity of FISH than that of cytolo-
gy, few investigations for usefulness of FISH have been per-
formed in clinical practice. Moreover, it is unclear which cases
did FISH help to detect BUC. Our results also show that FISH
had a significantly higher sensitivity than did cytology for
the detection of all tumors including superficial/invasive and
low/high-grade cases as previously reported. In addition, the
sensitivity of FISH was higher than that of cytology for new
cases of UC as well as recurrent cases. 
The collected volume of urine for FISH or cytology was
more than 40 mL, respectively in this study, thus avoiding
problems caused by insufficient sample. Nevertheless, the
sensitivity of FISH and cytology, in the present study, was
unexpectedly lower than in several prior reports (6, 11, 13,
14). The possible explanations for these findings are as fol-
lows: 1) Different tumor sizes, grade and stage in each study;
it is known that tumor size, grade and stage influence sensi-
tivity and specificity of urine testing for bladder tumor (15,
16). The population of this study included 102 (83.6%) pa-
tients with superficial tumors and 78 (63.9%) with low grade
tumors. Based on the tumor size, there were 83 patients with
tumors 1 cm or less, 23 with 3 cm or less and 16 with tumors
more than 3 cm. The tumor characteristics of our population
may have resulted in the FISH and cytology sensitivity being
lower than that of other studies. 2) The method of collection
of the urine specimen, from bladder washing versus voided
urine. According to the study of Bhuiyan et al. (17), a com-
paratively higher sensitivities of urinary tumor marker with
cystoscopically collected urine or bladder wash than that of
voided urine samples were observed. Urine specimens were
exclusively collected from voided urine in this study. 3) The
disparity of the study cohorts reflected by the fact that nor-
mal healthy volunteers, as well as the patients who underwent
transurethral resection of prostate (TURP) for benign prostatic
hyperplasia (BPH), were included in other studies as controls
(11, 12, 14). All participants in this study were cases under
surveillance for BUC in the clinical practice setting. 4) The
differences of applied criteria used for FISH positive results
among studies. According to several prior reports, a variety
of criteria has been applied for FISH positive results, never-
theless, the optimal criteria to define FISH-positive results
are not absolutely clear (7, 8, 18, 19). In some investigations,
a specimen was considered FISH positive for BC if ten or more
cells with gain of a single chromosome or if ten or more cells
with homozygous loss of the 9p21 locus (18, 19). In this study,
fifteen patients with false-negative FISH had at least one cell
with an abnormal signal pattern consistent with polysomy
of chromosome 3, 7, 17, and 9p21. We regard our criteria
for FISH positive results as more strict than those of previ-
ous studies. 
Among 59 patients who had had a history of BUC with or
without upper tract UC, 19 underwent intravesical immuno-
therapy. Twelve of these patients were positive on FISH and
Fig. 4. Sensitivity based on histologic grade.
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9 had a recurred BUC. Because intravesical therapy might
cause false-positive result of urine test for detecting BUC (20)
and chromosomal integrity was not affected by intravesical
therapy (21, 22), it is not likely that intravesical therapy affect-
ed FISH result to show lower sensitivity of FISH than other
study.
Among 36 patients who had suspicious lesions without
visible tumor on cystoscopy, 15 were FISH-positive with dis-
cordant results (atypical or negative) on cytology. Thirteen
(86.7%) of them had BUC. In the subgroup of 78 patients
with low grade superficial tumor (pTa-pT1 with grade 1-2),
FISH was positive in 32 (41%), cytology either suggestive
of malignancy or positive in 14 (17.9%) and 10 had no def-
inite visible tumor on cystoscopy examination. In these pati-
ents, seven patients without visible tumor on cystoscopy were
atypical or negative in cytology and 6 of them had the posi-
tive results of FISH. However, none of the patients with neg-
ative results of FISH had the results suggestive of malignan-
cy or positive in cytology. The FISH-positive result seems to
provide a diagnostic clue in detecting BUC for these patients. 
FISH missed 54 patients with histologically confirmed
UC. The majority of them (51) were negative or atypical on
cytology, while only three had results suggestive of malig-
nancy or positive by cytology. Overall, 49 (90.7%) and 46
(85.2%) of 54 false-negative patients by FISH had superfi-
cial and low-grade tumors, respectively.
There were 18 false-positive results by FISH. Among them,
four patients had results suggestive of malignancy or positive
by cytology; TUR or biopsy was performed in two patients
with abnormal lesions on cystoscopy. The histopathology of
these cases was chronic inflammation and reactive urotheli-
um without malignancy. According to the report of Sarosdy
et al. (14), patients with false-positive FISH had a significantly
higher recurrence rate than those with a true-negative result.
Another investigation reported that multi-target FISH might
help to stratify the risk of UC recurrence, at the time of a nega-
tive cystoscopy, by using optimal criteria for FISH positive
results (8). Although two patients with false-positive FISH
had BUC diagnosed during follow-up, it is hard to assess the
clinical implication of the false-positive FISH results because
of the limited follow-up duration of this study. 
The limitations of this study include that it was a retro-
spective study and that the histopathology results were not
available in all patients because TUR or biopsy was deter-
mined by cystoscopy finding. However, cystoscopy, consid-
ered as the gold standard for the detection of BUC, was per-
formed to identify the presence or absence of bladder lesions
in all patients. Moreover, to exclude the influence of upper
tract UC on the analysis, the study population was restricted
to only patients being evaluated for BUC. Despite these limi-
tations, this study is one of few studies that compared the
performance characteristics of FISH and cytology in clinical
practice setting, unlike other studies which included normal
healthy volunteers and the patients with BPH as controls. 
In conclusion, the sensitivity of the FISH assay using chro-
mosomes 3, 7, 17, and 9p21 for the detection of BUC was
superior to that of urine cytology, regardless of the tumor
stage and grade, although FISH was slightly less specific than
cytology. Even if taking its high cost into consideration, FISH
may be a significant additional and complementary method
for the detection of BUC, especially in patients who have no
visible tumor but flat, erythematous mucosa (suspicious lesion)
on cystoscopy. 
REFERENCES
1. Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP. Biol-
ogy and management of bladder cancer. N Engl J Med 1990; 322:
1129-38.
2. Maier U, Simak R, Neuhold N. The clinical value of urinary cytolo-
gy: 12 years of experience with 615 patients. J Clin Pathol 1995;
48: 314-7.
3. Konety BR, Getzenberg RH. Urine based markers of urological
malignancy. J Urol 2001; 165: 600-11.
4. Lokeshwar VB, Soloway MS. Current bladder tumor tests: does their
projected utility fulfill clinical necessity? J Urol 2001; 165: 1067-77.
5. Glas AS, Roos D, Deutekom M, Zwinderman AH, Bossuyt PM,
Kurth KH. Tumor markers in the diagnosis of primary bladder can-
cer. A systematic review. J Urol 2003; 169: 1975-82.
6. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly avail-
able bladder tumor markers versus cytology: results of a comprehen-
sive literature review and meta-analyses. Urology 2003; 61: 109-18.
7. Sokolova IA, Halling KC, Jenkins RB, Burkhardt HM, Meyer RG,
Seelig SA, King W. The development of a multitarget, multicolor
fluorescence in situ hybridization assay for the detection of urothe-
lial carcinoma in urine. J Mol Diagn 2000; 2: 116-23.
8. Zellweger T, Benz G, Cathomas G, Mihatsch MJ, Sulser T, Gasser
TC, Bubendorf L. Multi-target fluorescence in situ hybridization in
bladder washings for prediction of recurrent bladder cancer. Int J
Cancer 2006; 119: 1660-5.
9. Mao L, Schoenberg MP, Scicchitano M, Erozan YS, Merlo A, Schwab
D, Sidransky D. Molecular detection of primary bladder cancer by
microsatellite analysis. Science 1996; 271: 659-62.
10. Halling KC, King W, Sokolova IA, Meyer RG, Burkhardt HM, Halling
AC, Cheville JC, Sebo TJ, Ramakumar S, Stewart CS, Pankratz S,
O’Kane DJ, Seelig SA, Lieber MM, Jenkins RB. A comparison of
cytology and fluorescence in situ hybridization for the detection of
urothelial carcinoma. J Urol 2000; 164: 1768-75.
11. Placer J, Espinet B, Salido M, Sole F, Gelabert-Mas A. Clinical utili-
ty of a multiprobe FISH assay in voided urine specimens for the detec-
tion of bladder cancer and its recurrences, compared with urinary
cytology. Eur Urol 2002; 42: 547-52.
12. Marin-Aguilera M, Mengual L, Ribal MJ, Burset M, Arce Y, Ars E,
Oliver A, Villavicencio H, Algaba F, Alcaraz A. Utility of a multi-
probe fluorescence in situ hybridization assay in the detection of super-
ficial urothelial bladder cancer. Cancer Genet Cytogenet 2007; 173:
131-5.1144 K.W. Kwak, S.H. Kim, and H.M. Lee
13. Halling KC, King W, Sokolova IA, Karnes RJ, Meyer RG, Powell
EL, Sebo TJ, Cheville JC, Clayton AC, Krajnik KL, Ebert TA, Nel-
son RE, Burkhardt HM, Ramakumar S, Stewart CS, Pankratz VS,
Lieber MM, Blute ML, Zincke H, Seelig SA, Jenkins RB, O’Kane
DJ. A comparison of BTA stat, hemoglobin dipstick, telomerase and
Vysis UroVysion assays for the detection of urothelial carcinoma in
urine. J Urol 2002; 167: 2001-6.
14. Sarosdy MF, Schellhammer P, Bokinsky G, Kahn P, Chao R, Yore
L, Zadra J, Burzon D, Osher G, Bridge JA, Anderson S, Johansson
SL, Lieber M, Soloway M, Flom K. Clinical evaluation of a multi-
target fluorescent in situ hybridization assay for detection of blad-
der cancer. J Urol 2002; 168: 1950-4.
15. Raitanen MP, Marttila T, Kaasinen E, Rintala E, Aine R, Tammela
TL. Sensitivity of human complement factor H related protein (BTA
stat) test and voided urine cytology in the diagnosis of bladder can-
cer. J Urol 2000; 163: 1689-92.
16. Boman H, Hedelin H, Holmang S. Four bladder tumor markers have
a disappointingly low sensitivity for small size and low grade recur-
rence. J Urol 2002; 167: 80-3.
17. Bhuiyan J, Akhter J, O’Kane DJ. Performance characteristics of mul-
tiple urinary tumor markers and sample collection techniques in the
detection of transitional cell carcinoma of the bladder. Clin Chim
Acta 2003; 331: 69-77.
18. Bubendorf L, Grilli B, Sauter G, Mihatsch MJ, Gasser TC, Dalquen
P. Multiprobe FISH for enhanced detection of bladder cancer in void-
ed urine specimens and bladder washings. Am J Clin Pathol 2001;
116: 79-86.
19. Junker K, Fritsch T, Hartmann A, Schulze W, Schubert J. Multicol-
or fluorescence in situ hybridization (M-FISH) on cells from urine
for the detection of bladder cancer. Cytogenet Genome Res 2006;
114: 279-83.
20. Raitanen MP, Kaasinen E, Lukkarinen O, Kauppinen R, Viitanen J,
Liukkonen T, Tammela TL. Analysis of false-positive BTA STAT
test results in patients followed up for bladder cancer. Urology 2001;
57: 680-4.
21. Pycha A, Mian C, Hofbauer J, Haitel A, Wiener H, Marberger M.
Does topical instillation therapy influence chromosomal aberrations
in superficial bladder cancer? J Urol 1998; 159: 265-9.
22. Friedrich MG, Toma MI, Hellstern A, Pantel K, Weisenberger DJ,
Noldus J, Huland H. Comparison of multitarget fluorescence in situ
hybridization in urine with other noninvasive tests for detecting blad-
der cancer. BJU Int 2003; 92: 911-4.